Natural food and supplement ingredient firm Naturex enters the market for urinary tract infection remedies by acquiring Decas Cranberry Products Inc.’s cranberry nutraceutical business, Decas Botanical Synergies LLC. Carver, Mass.-based Decas Botanical’s portfolio includes cranberry-derived standardized powders and extracts, juice concentrate powders and cold-pressed seed oils for ingredients in supplements, functional foods and other products. France-based Naturex Sept. 19 said in the U.S. Decas Botanical’s PACran can be labeled “helps support urinary tract health.” The deal also includes a long-term agreement for Decas Cranberry to supply materials to Naturex. The firm acquired 95% of Decas Botanical with Decas’ CEO Doug Klaiber retaining the remaining 5%; other terms of the deal were not disclosed.
In Brief
Naturex acquires Decas to enter UTI ingredient market; TSI finalizes Yessamin deal; NattoPharma gains U.S. patent for vitamin K2; DSM appoints Goppelsroeder nutritionals head; more news in brief.
More from United States
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
One CDRH employee said the cuts already are having a major effect on morale.
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
More from North America
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."